Document is current
Any future updates will be listed below
-
Authors
Kopolrat, Kulthida Y. https://orcid.org/0000-0001-6114-6554
Singthong, Seri
Khuntikeo, Narong
Loilome, Watcharin
Worasith, Chanika
Homwong, Chutima
Wangboon, Chompunoot
Yasaka, Patiwat
Eamudomkarn, Chatanun
Pitaksakulrat, Opal
Tonkhamhak, Krisnakorn
Paeyo, Arunee
Crellen, Thomas https://orcid.org/0000-0003-2934-1063
Sithithaworn, Jiraporn
Sithithaworn, Paiboon
-
Funding
Funding for this research was provided by:
National Research Council of Thailand
Wellcome Trust (215919/Z/19/Z)
- License Information
-
More Information
Article History
Received: 1 February 2022
Accepted: 24 May 2022
First Online: 27 June 2022
Declarations
:
: The human experimental protocol was approved by the Khon Kaen University Ethics Committee (Reference number HE601370). Only subjects who provided written informed consent were recruited. Treatment with a single oral dose of PZQ (40 mg/kg body weight) was given to subjects who were diagnosed as <i>O. viverrini</i>-positive by the FECT and/or urine antigen detection assay. Subjects who were found positive for other parasitic infections were given appropriate anthelmintic drugs.
: Not applicable.
: The authors declare that they have no competing interests.
